Berenberg Bank analyst Berenberg Bank maintained a Buy rating on BioNTech SE (BNTX) yesterday and set a price target of $98.00. The company’s shares closed last Tuesday at $67.05.
BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $83.42, representing a 27.6% upside. In a report issued on September 9, Canaccord Genuity also maintained a Buy rating on the stock with a $97.00 price target.
See today’s analyst top recommended stocks >>
Based on BioNTech SE’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $41.76 million and GAAP net loss of $88.3 million. In comparison, last year the company earned revenue of $25.79 million and had a GAAP net loss of $50.08 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany.
Read More on BNTX:
